Smartwatches track hidden heart risk in blood cancer patients
NCT ID NCT07711327
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study investigates how often atrial fibrillation (AF), a type of irregular heartbeat, occurs in people with certain blood cancers who are starting a targeted cancer drug called a Bruton's tyrosine kinase inhibitor (BTKI). Researchers will follow 500 participants—400 starting BTKI therapy and 100 with similar cancers not on BTKIs—using smartwatches and heart monitor patches to detect AF and other rhythm problems over 12 months. The goal is to understand whether BTKI therapy raises the risk of AF and how that might affect cancer treatment and overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bruton's tyrosine kinase inhibitor (BTKI) therapy
- What this could lead to
- If this study finds a clear link, it could help doctors monitor and manage heart rhythm problems in blood cancer patients on BTKI therapy.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. The results may not apply to all patients or cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
Duarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford Health Care
Stanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UC San Diego Health
San Diego, California, 92103, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which ablation method best tames persistent AF? a Head-to-Head trial aims to find out
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can zapping an extra vein stop atrial fibrillation better?
- Heart surgery for athletes: does zapping faulty signals boost or bust performance?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Can an AI spot a heart rhythm disorder two hours before it happens?